Work

722eTiP Interim analysis of a phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with Standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.1296

Authors: B. Stockdale, S. Nagpal, A. Cohen, C. Patil, B. Vaillant, K. Elmore, A.J. Brenner, R. Juthani, D.A. Reardon, R. Kendle, A.I. Spira, J. Wykretowicz, V. Zhukova-Harrill, B. Nie, N.R. Narain, V. Modur

Institutions: Stanford University, Cedars-Sinai Medical Center, Icahn School of Medicine at Mount Sinai, Mays Cancer Center at UT Health San Antonio, Valley Hospital, Valley Health System, Dana-Farber Cancer Institute, Sansum Medical Clinic, Virginia Cancer Specialists, Virginia Oncology Associates, BPGbio, Inc. (United States)

Language: English

Topic: Coenzyme Q10 studies and effects

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415940315

FWCI:

Cites:

Cited by:

Related to: